Abbott Laboratories On Track for Largest Percent Decrease Since October 2023 — Data Talk
Abbott Laboratories (ABT) is currently at $113.79, down $5.06 or 4.26%
--Would be lowest close since Feb. 15, 2024, when it closed at $113.64
--On pace for largest percent decrease since Oct. 11, 2023, when it fell 5.04%
--Currently down four of the past five days
--Currently down three consecutive days; down 5.77% over this period
--Worst three day stretch since the three days ending Oct. 13, 2023, when it fell 6.86%
--Down 4.09% month-to-date
--Up 3.38% year-to-date
--Down 19.56% from its all-time closing high of $141.46 on Dec. 27, 2021
--Up 17.3% from 52 weeks ago (March 17, 2023), when it closed at $97.01
--Down 5.93% from its 52-week closing high of $120.96 on March 8, 2024
--Up 26.17% from its 52-week closing low of $90.19 on Oct. 12, 2023
--Traded as low as $112.26; lowest intraday level since Feb. 14, 2024, when it hit $111.12
--Down 5.54% at today's intraday low; largest intraday percent decrease since Oct. 11, 2023, when it fell as much as 5.65%
--Fourth worst performer in the S&P 500 today
All data as of 10:14:33 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
March 15, 2024 10:33 ET (14:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks